Navigation Links
Chemo Combo Shows Promise Against Ovarian Cancer
Date:4/19/2009

Lab-based study focused on certain types of malignancies

SUNDAY, April 19 (HealthDay News) -- Adding the drug dasatinib to a standard, two-drug chemotherapy regimen for treating ovarian cancer boosted the effectiveness of the drugs in laboratory tests, new research shows.

Researchers at the Duke Comprehensive Cancer Center added dasatinib, along with carboplatin and paclitaxel, to four types of ovarian cancer cells.

In some types of ovarian cancers, a pathway called SRC is involved in the abnormal cell proliferation, said Dr. Deanna Teoh, a fellow in gynecologic oncology at Duke and lead investigator on this study.

"By examining gene expression data, we determined that the combination of the leukemia drug dasatinib (Sprycel) made carboplatin and paclitaxel more effective in cell lines with higher levels of SRC expression and SRC pathway deregulation," Teoh said.

Dasatinib, which is marketed by Bristol-Meyers Squibb under the brand name Sprycel, is FDA-approved for treating leukemia.

"These findings indicate that we may be able to direct the use of a targeted therapy like dasatinib based on gene expression pathways in select ovarian cancers," she said.

The results of the study were to be presented Sunday at the American Association for Cancer Research annual meeting, in Denver.

Researchers examined four ovarian cancer cell lines, known as IGROV1, SKOV3, OVCAR3 and A2780. Three of the cell lines demonstrated high activation of SRC, and one demonstrated lower SRC expression. All were treated in lab dishes with various combinations of the chemotherapy drugs dasatinib, carboplatin and paclitaxel.

"We found that the addition of dasatinib to standard therapy in the three cell lines with significant SRC pathway deregulation -- IGROV1, OVCAR3 and A2780 -- enhanced the response of the cancer cells to therapy," Teoh said. "Conversely, in SKOV3, which has minimal SRC protein expression and pathway deregulation, we saw the least amount of anti-cancer activity when we added dasatinib."

The results of the study support further investigation of targeted biologic therapy using a SRC inhibitor in some ovarian cancers, Teoh said. Currently a phase 1 trial of a combination of dasatinib, paclitaxel and carboplatin is available for women with advanced or recurrent ovarian, tubal and peritoneal cancers, the researchers said.

More information

The American Cancer Society has more on ovarian cancer.



-- Jennifer Thomas



SOURCE: Duke Comprehensive Cancer Center news release, April 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
8. Medicare modernization act did not change chemotherapy as feared
9. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
10. Cancer conflict with chemotherapy treatment
11. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today ... for active, healthy lifestyles and highlighting the importance of proactive eye and ear ... and shares the latest innovations in hearing aid technology. , In this ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & ... assistance to communities in North-Central West Virginia, is embarking on a cooperative charity ... in the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding ...
(Date:8/18/2017)... Humble, TX (PRWEB) , ... August 18, 2017 ... ... insurance management and financial planning firm that serves residential and commercial clients in ... a charity drive to raise community support for the fight against cancer. , ...
(Date:8/18/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released ... pertaining to the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says ... the role of this historical woman. , “The world bows, kisses the feet of, ...
(Date:8/18/2017)... ... , ... “Our Mountains to Climb: A Journey of Love and Faith Through ... through the faith they shared to overcome struggles in life. “Our Mountains to Climb: ... Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s personal ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
Breaking Medicine Technology: